EP3472620A2 - Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde - Google Patents

Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde

Info

Publication number
EP3472620A2
EP3472620A2 EP17737723.1A EP17737723A EP3472620A2 EP 3472620 A2 EP3472620 A2 EP 3472620A2 EP 17737723 A EP17737723 A EP 17737723A EP 3472620 A2 EP3472620 A2 EP 3472620A2
Authority
EP
European Patent Office
Prior art keywords
seq
group
patients
therapy
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17737723.1A
Other languages
German (de)
English (en)
Inventor
Petra Budde
Angelika LÜKING
Peter Schulz-Knappe
Hans-Dieter Zucht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncimmune Germany GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen GmbH filed Critical Protagen GmbH
Publication of EP3472620A2 publication Critical patent/EP3472620A2/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

L'invention concerne un procédé pour le suivi thérapeutique de patients et (sous-)populations de patients (répondants/non répondants) présentant une polyarthrite rhumatoïde (PR), ainsi que l'utilisation de séquences de marqueur adaptées, en particulier sous forme de panels, d'agents de diagnostic et de trousses d'analyse, et leur utilisation et application pour le diagnostic, pronostic et suivi thérapeutique d'une polyarthrite rhumatoïde (PR), en particulier lors d'un traitement médicamenteux.
EP17737723.1A 2016-06-15 2017-06-15 Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde Pending EP3472620A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16174672.2A EP3258268A1 (fr) 2016-06-15 2016-06-15 Sequences de marqueurs pour la commande de therapie de patients atteints de polyarthrite rhumatoïde
PCT/EP2017/064728 WO2017216323A2 (fr) 2016-06-15 2017-06-15 Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde

Publications (1)

Publication Number Publication Date
EP3472620A2 true EP3472620A2 (fr) 2019-04-24

Family

ID=56148166

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16174672.2A Withdrawn EP3258268A1 (fr) 2016-06-15 2016-06-15 Sequences de marqueurs pour la commande de therapie de patients atteints de polyarthrite rhumatoïde
EP17737723.1A Pending EP3472620A2 (fr) 2016-06-15 2017-06-15 Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16174672.2A Withdrawn EP3258268A1 (fr) 2016-06-15 2016-06-15 Sequences de marqueurs pour la commande de therapie de patients atteints de polyarthrite rhumatoïde

Country Status (3)

Country Link
US (1) US20190128884A1 (fr)
EP (2) EP3258268A1 (fr)
WO (1) WO2017216323A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111118012B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0051680表达的siRNA及其应用
CN114414812B (zh) * 2020-12-21 2022-09-20 华中科技大学同济医学院附属同济医院 生物标志物组合在制备暴发性心肌炎诊断试剂及暴发性心肌炎药物方面的应用
KR102520048B1 (ko) * 2021-06-02 2023-04-11 가톨릭대학교 산학협력단 류마티스 관절염의 치료 반응성 예측용 바이오마커
AU2022375208A1 (en) * 2021-10-29 2024-05-02 GenoDx Pty Ltd Biomarkers and uses therefor
CN114184783A (zh) * 2021-12-07 2022-03-15 陕西脉元生物科技有限公司 抗ppp1r9b抗体的试剂在制备诊断和/或治疗神经系统自身免疫疾病试剂盒中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
WO1999057312A1 (fr) 1998-04-30 1999-11-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveau procede permettant la selection de clones dans une banque d'expression et comprenant un rearrangement
EP1073770B1 (fr) 1998-04-30 2004-11-17 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Nouveau procede permettant l'identification de clones conferant une propriete biologique desiree dans une banque d'expression
EP2255195A2 (fr) 2007-09-03 2010-12-01 Protagen AG Séquences de marqueurs de la polyarthrite rhumatoïde et leur utilisation
EP2204655A1 (fr) * 2008-12-23 2010-07-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prédiction de diagnostic de l'arthrite rhumatoïde et lupus érythémateux systémique
WO2011097527A2 (fr) * 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection de fractions thérapeutiques avec des régions fc améliorées
WO2013170994A1 (fr) * 2012-03-27 2013-11-21 Protagen Ag Séquences marqueurs de la polyarthrite rhumatoïde
US10746735B2 (en) * 2014-02-10 2020-08-18 Oncimmune Germany Gmbh Marker sequences for diagnosing and stratifying SLE patients

Also Published As

Publication number Publication date
WO2017216323A3 (fr) 2018-02-08
EP3258268A1 (fr) 2017-12-20
WO2017216323A2 (fr) 2017-12-21
US20190128884A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
EP3472620A2 (fr) Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde
US20180106817A1 (en) Protein biomarkers and therapeutic targets for renal disorders
TWI788704B (zh) 分析個體樣品之方法
JP5749171B2 (ja) バイオマーカー
EP2971285B1 (fr) Biomarqueurs sanguins prédisant la persistance d'un dysfonctionnement cognitif après commotion
US20120004130A1 (en) Autoimmune disease biomarkers
EP3105591B1 (fr) Séquences de marqueurs pour le diagnostic et la stratification de patients atteints de sle
EP3710831A1 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
EP2607900A1 (fr) Séquences de marqueurs pour cancer du sein et leur utilisation
EP3140651B1 (fr) Séquences de marqueurs pour le diagnostic et la stratification des patients atteints de sclérose systémique
EP2831275A1 (fr) Séquences marqueurs de la polyarthrite rhumatoïde
KR102328932B1 (ko) 신장이식 후 항체 매개성 거부반응의 진단 또는 예측을 위한 소변 엑소좀 바이오마커
US20150338412A1 (en) Composition for diagnosis of lung cancer and diagnosis kit for lung cancer
JP5924502B2 (ja) リンパ球性漏斗下垂体後葉炎のバイオマーカー及びその用途
EP2712932A2 (fr) Séquences de marqueurs pour les maladies avec inflammation de la prostate, carcinome de la prostate et leur utilisation
CN109891241B (zh) 能够进行糖尿病性肾病的早期病情的特异性诊断的检查方法
EP3436828A1 (fr) Séquences de marqueurs pour la polyarthrite rhumatoïde
EP2735875A1 (fr) Séquences de marqueurs de la neuromyélite optique (NMO) et son utilisation
EP2772759A1 (fr) Composition pour diagnostic du cancer des poumons
CN113430263B (zh) 基于生物标志物的诊断青光眼的产品及其应用
EP2644704A1 (fr) Séquences de marqueurs pour l'arthrite rhumatoïde
CN112011604A (zh) 一种用于评估重症肌无力风险的微生物标志物及其应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTAGEN GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ONCIMMUNE GERMANY GMBH

PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230223

B565 Issuance of search results under rule 164(2) epc

Effective date: 20230223

RIC1 Information provided on ipc code assigned before grant

Ipc: C40B 40/02 20060101ALI20230220BHEP

Ipc: C40B 30/04 20060101ALI20230220BHEP

Ipc: C07K 17/00 20060101ALI20230220BHEP

Ipc: G01N 33/564 20060101AFI20230220BHEP